News

Europe’s firms ramp up R&D
Enlarge image

BusinessEU

Europe’s firms ramp up R&D

07.12.2012 - According to the 2011 EU Industrial R&D Investment Scoreboard, the 400 leading European companies invested about €132bn, a plus of 6.1% over 2009.

R&D investment by top EU companies recovered strongly in 2010. The annually published Scoreboard collects information on the top 1000 EU companies and 1000 non-EU companies investing the largest sums in research and development. What seems to be a positive trend as a first glance, shows some worrying trends at closer inspection. The study, which was commissioned by the European Commission, has shown that EU companies as a whole are lagging behind major competitors from the US and some Asian economies on R&D growth. While EU-based companies increased R&D expenditures by 6.1%, US-companies have spent 10% more. The increase was even larger in Taiwan (17.8%), South Korea (20.5%) and China(29.5%).

The global top 50, in terms of total R&D investment, includes 15 EU companies, 18 US firms and 13 from Japan. Two pharmaceutical companies occupied the top spots: Roche from Switzerland (€7.2bn) followed by Pfizer from the US (€7bn). A ray of light: A poll with some 190 mainly larger EU-companies surveyed in the Scoreboard revealed that they expect to maintain robust R&D investment increases (average 4% p.a.) over the next three years. This could be seen as a positive and stable trend for R&D investment growth, as observed before the 2008 economic and financial crises.

The Pharmaceuticals & Biotechnology sector has strengthened its position as the largest sector for R&D, its expenditures grew by 6.2% in 2010, slightly more than in 2009. The other two top sectors, Technology Hardware & Equipment and Automobiles & Parts are recovering from the significant reductions observed in the past Scoreboard (from -6.4% to 3.5% and from -11.6% to 0% respectively). Interestingly, all three sectors increased net sales more than they increased R&D investments.

Máire Geoghegan-Quinn, Commissioner for Research, Innovation and Science sees room for further improvement. „We need quick adoption and implementation of recent and up-coming European Commission proposals on the unitary patent, on standards, public procurement and risk capital“, she said. 

© eurobiotechnews.eu/bk

http://www.european-biotechnology-news.com/news/news/2012-04/europes-firms-ramp-up-rd.html

AntibodiesDenmarkNetherlands

22.05.2015 Dutch arGEN-X and Danish LEO Pharma are pairing up to develop antibody-based treatments for the chronic inflammation that causes many skin conditions.

M&ANetherlandsGermanyEU

12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.

Rare diseasesItalyGermanyPoland

15.05.2015 Rome-based pharmaceutical group Sigma-Tau has sold its blood cancer drug programme Oncaspar to US company Baxter, who aims to spin out its biopharma business.



SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&AUKSweden

18.05.2015 Double deal for allergy: UK’s speciality biopharma Circassia is boosting its asthma pipeline with the acquisition of Swedish asthma specialist Aerocrine as well as fellow British Prosonix.

FinancingUK

20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto to discuss a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

FinancingSwitzerlandUK

29.04.2015 Biopharma start-up CRISPR Therapeutics has raised US$64m to hurry the new CRISPR/Cas9 technology to the clinic.

Events

All Events

Partner-Events

Frankfurt am Main (DE)

ACHEMA 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • EVOTEC4.06 EUR4.10%
  • VITA 345.72 EUR3.06%
  • SARTORIUS165.00 EUR2.77%

FLOP

  • CYTOS0.65 CHF-4.41%
  • WILEX4.06 EUR-4.02%
  • CO.DON2.80 EUR-3.78%

TOP

  • 4SC4.61 EUR274.8%
  • SYNGENTA422.10 CHF29.1%
  • WILEX4.06 EUR26.9%

FLOP

  • CYTOS0.65 CHF-36.3%
  • MEDIGENE9.02 EUR-31.1%
  • BIOTEST76.17 EUR-22.3%

TOP

  • WILEX4.06 EUR401.2%
  • CYTOS0.65 CHF364.3%
  • 4SC4.61 EUR319.1%

FLOP

  • MOLOGEN4.89 EUR-54.7%
  • BIOFRONTERA2.30 EUR-24.1%
  • CO.DON2.80 EUR-23.7%

No liability assumed, Date: 21.05.2015